Post-surgery safety study of durvalumab for resectable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tracks the safety of the drug durvalumab (an immunotherapy that helps the immune system fight cancer) when given to adults with early-stage, resectable lung cancer (non-small cell lung cancer, NSCLC). The goal is to see how well patients tolerate the treatment in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with non-small cell lung cancer (NSCLC) that can be surgically removed (resectable) and has not been treated yet.
- The tumor is at least 4 cm in size and/or has spread to nearby lymph nodes (node positive).
- Your cancer does not have certain gene mutations (EGFR mutations or ALK rearrangements), which your doctor checks with a test.
- Your doctor has prescribed durvalumab as part of your treatment plan.
- You do not have other cancers that need treatment at the same time, and you are not participating in any other clinical trials.
- You do not have an active autoimmune disease or a condition that required corticosteroids or immunosuppressants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 study tests durvalumab plus IPH5201 given before surgery to improve outcomes for people with resectable non-small cell lung cancer. It aims to shrink or control the cancer and make surgery more effective, using information about specific tumor markers like PD-L1.
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This study tests a special dye attached to durvalumab (a cancer drug) to see if it can light up tumors in the lungs during a bronchoscopy. It will help doctors see if the drug reaches the cancer cells and may guide future treatments.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.